Qubit Pharmaceuticals develops novel drug candidates and modes of action against complex targets, including RNA, using the ATLAS platform for high-precision molecular modeling, simulation, and molecule generation. It advances proprietary and partnered programs targeting oncology (KAT6A, RAS/RAF, Malat-1, LIN28), inflammation (IL4R), and pandemic response (TREX1, undisclosed GPCR). The platform leverages quantum physics to solve Schrödinger's equation with high accuracy, AI-enhanced medicinal chemistry, polarizable force fields for 1000ns MD simulations per day, and hybrid HPC-quantum computing capabilities over 30 qubits and 50 PetaFLOPS. Founded in 2020 by Jay Ponder (professor of chemistry and biomedical engineering at Washington University in St. Louis), Pengyu Ren (professor at University of Texas at Austin), Jean-Philip Piquemal (professor of theoretical chemistry at Sorbonne University), Matthieu Montes (professor of bioinformatics at CNAM), and Louis Lagardère (research engineer at Sorbonne University), with Robert Marino (PhD, prior startup development experience) as CEO. The company raised €16.1 million seed round in 2022 from XAnge, Omnes Capital, Quantonation and others, with total funding of $28.7 million including a $2.34 million later-stage VC round in October 2025. Headquartered at 29 rue du Faubourg Saint Jacques in Paris, France, it operates additional offices in Boston and Chicago.